Skip to main content
Erschienen in: AIDS and Behavior 11/2014

01.11.2014 | Original Paper

Correlates of Unstructured Antiretroviral Treatment Interruption in a Cohort of HIV-Positive Individuals in British Columbia

verfasst von: Hasina Samji, Yalin Chen, Kate Salters, Julio S. G. Montaner, Robert S. Hogg

Erschienen in: AIDS and Behavior | Ausgabe 11/2014

Einloggen, um Zugang zu erhalten

Abstract

Treatment interruptions (TIs) limit the therapeutic success of combination antiretroviral therapy and are associated with higher morbidity and mortality. HIV-positive individuals dealing with concurrent health issues, access challenges and competing life demands are hypothesized to be more likely to interrupt treatment. Individuals were included if they initiated cART ≥1 year prior to interview date and had a CD4 cell count and initial regimen recorded at initiation. Using pharmacy recording, a TI was defined as a patient-initiated gap in treatment ≥90 consecutive days during the 12 months preceding or following the study interview. 117 (15.2 %) of 768 participants included in this study had a TI during the study window. 76.0 % of participants were male, 27.5 % were of Aboriginal ancestry and the median age was 46 (interquartile range 40–52). In multivariable logistic regression, TIs were significantly associated with current illicit drug use (adjusted odds ratio [aOR] 1.68, 95 % confidence interval [CI] 1.05–2.68); <95 % adherence in the first year of treatment (aOR 2.68, 95 % CI 1.67–4.12); living with at least one person (aOR 1.95; 95 % CI 1.22–3.14) or living on the street (aOR 5.08, 95 % CI 1.72–14.99) compared to living alone; poor perception of overall health (aOR 1.64 95 % CI 1.05–2.55); being unemployed (aOR: 2.22, 95 % CI 1.16–4.23); and younger age at interview (aOR 0.57, 95 % CI 0.44–0.75, per 10 year increase). Addressing socioeconomic barriers to treatment retention is vital for supporting the continuous engagement of patients in care.
Literatur
1.
Zurück zum Zitat Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52(6):793–800.PubMedPubMedCentralCrossRef Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52(6):793–800.PubMedPubMedCentralCrossRef
2.
Zurück zum Zitat Bae JW, Guyer W, Grimm K, Altice FL. Medication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research. AIDS. 2011;25(3):279–90.PubMedCrossRef Bae JW, Guyer W, Grimm K, Altice FL. Medication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research. AIDS. 2011;25(3):279–90.PubMedCrossRef
3.
Zurück zum Zitat Montaner JS, Lima VD, Barrios R, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet. 2010;376(9740):532–9.PubMedPubMedCentralCrossRef Montaner JS, Lima VD, Barrios R, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet. 2010;376(9740):532–9.PubMedPubMedCentralCrossRef
4.
Zurück zum Zitat Lima VD, Johnston K, Hogg RS, et al. Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis. 2008;198(1):59–67.PubMedCrossRef Lima VD, Johnston K, Hogg RS, et al. Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis. 2008;198(1):59–67.PubMedCrossRef
5.
6.
Zurück zum Zitat Walmsley S, Loutfy M. Can structured treatment interruptions (STIs) be used as a strategy to decrease total drug requirements and toxicity in HIV infection? J Int Assoc Physicians AIDS Care (Chic). 2002 Summer;1(3):95–103. Walmsley S, Loutfy M. Can structured treatment interruptions (STIs) be used as a strategy to decrease total drug requirements and toxicity in HIV infection? J Int Assoc Physicians AIDS Care (Chic). 2002 Summer;1(3):95–103.
7.
Zurück zum Zitat Ananworanich J, Gayet-Ageron A, Le Braz M, et al. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet. 2006;368(9534):459–65.PubMedCrossRef Ananworanich J, Gayet-Ageron A, Le Braz M, et al. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet. 2006;368(9534):459–65.PubMedCrossRef
8.
Zurück zum Zitat Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355(22):2283–96.PubMedCrossRef Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355(22):2283–96.PubMedCrossRef
9.
Zurück zum Zitat SMART Study Group, El-Sadr WM, Grund B, et al. Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann Intern Med. 2008;149(5):289–299. SMART Study Group, El-Sadr WM, Grund B, et al. Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann Intern Med. 2008;149(5):289–299.
10.
Zurück zum Zitat Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008;300(5):555–70.PubMedCrossRef Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008;300(5):555–70.PubMedCrossRef
11.
Zurück zum Zitat DART Trial Team. Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts <200 cells/microl. AIDS. 2008;22(2):237–47.CrossRef DART Trial Team. Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts <200 cells/microl. AIDS. 2008;22(2):237–47.CrossRef
12.
Zurück zum Zitat Seminari E, De Silvestri A, Boschi A, Tinelli C. CD4+ guided antiretroviral treatment interruption in HIV infection: a meta-analysis. AIDS Rev. 2008;10(4):236–44.PubMed Seminari E, De Silvestri A, Boschi A, Tinelli C. CD4+ guided antiretroviral treatment interruption in HIV infection: a meta-analysis. AIDS Rev. 2008;10(4):236–44.PubMed
13.
Zurück zum Zitat Harrigan PR, Whaley M, Montaner JS. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS. 1999;13(8):F59–62.PubMedCrossRef Harrigan PR, Whaley M, Montaner JS. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS. 1999;13(8):F59–62.PubMedCrossRef
14.
Zurück zum Zitat Kilby JM, Goepfert PA, Miller AP, et al. Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: a case report. Ann Intern Med. 2000;133(6):435–8.PubMedCrossRef Kilby JM, Goepfert PA, Miller AP, et al. Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: a case report. Ann Intern Med. 2000;133(6):435–8.PubMedCrossRef
15.
Zurück zum Zitat Deeks SG. International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance. J Acquir Immune Defic Syndr. 2001;26 Suppl 1:S25–S33. Deeks SG. International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance. J Acquir Immune Defic Syndr. 2001;26 Suppl 1:S25–S33.
16.
Zurück zum Zitat Teicher E, Casagrande T, Vittecoq D. Enhanced risk of HIV sexual transmission during structured treatment interruption. Sex Transm Infect. 2003;79(1):74.PubMedPubMedCentralCrossRef Teicher E, Casagrande T, Vittecoq D. Enhanced risk of HIV sexual transmission during structured treatment interruption. Sex Transm Infect. 2003;79(1):74.PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14(4):357–66.PubMedCrossRef Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14(4):357–66.PubMedCrossRef
18.
Zurück zum Zitat Dybul M. Structured treatment interruption: approaches and Risks. Curr Infect Dis Rep. 2002;4(2):175–80.PubMedCrossRef Dybul M. Structured treatment interruption: approaches and Risks. Curr Infect Dis Rep. 2002;4(2):175–80.PubMedCrossRef
19.
Zurück zum Zitat Pai NP, Tulsky JP, Lawrence J, Colford JM Jr, Reingold AL. Structured treatment interruptions (STI) in chronic suppressed HIV infection in adults. Cochrane Database Syst Rev. 2005;4(4):CD005482. Pai NP, Tulsky JP, Lawrence J, Colford JM Jr, Reingold AL. Structured treatment interruptions (STI) in chronic suppressed HIV infection in adults. Cochrane Database Syst Rev. 2005;4(4):CD005482.
20.
Zurück zum Zitat Calmy A, Nguyen A, Montecucco F, for the STACCATO Study Team. HIV activates markers of cardiovascular risk in a randomized treatment interruption trial: STACCATO. Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections 2008. Calmy A, Nguyen A, Montecucco F, for the STACCATO Study Team. HIV activates markers of cardiovascular risk in a randomized treatment interruption trial: STACCATO. Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections 2008.
21.
Zurück zum Zitat Moore DM, Zhang W, Yip B, et al. Non-medically supervised treatment interruptions among participants in a universally accessible antiretroviral therapy programme. HIV Med. 2010;11(5):299–307.PubMedCrossRef Moore DM, Zhang W, Yip B, et al. Non-medically supervised treatment interruptions among participants in a universally accessible antiretroviral therapy programme. HIV Med. 2010;11(5):299–307.PubMedCrossRef
22.
Zurück zum Zitat Kerr T, Marshall A, Walsh J, et al. Determinants of HAART discontinuation among injection drug users. AIDS Care. 2005;17(5):539–49.PubMedCrossRef Kerr T, Marshall A, Walsh J, et al. Determinants of HAART discontinuation among injection drug users. AIDS Care. 2005;17(5):539–49.PubMedCrossRef
23.
Zurück zum Zitat Yuan Y, L’italien G, Mukherjee J, Iloeje UH. Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort. HIV Med. 2006;7(3):156–62.PubMedCrossRef Yuan Y, L’italien G, Mukherjee J, Iloeje UH. Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort. HIV Med. 2006;7(3):156–62.PubMedCrossRef
24.
Zurück zum Zitat Ahdieh Grant L, Silverberg MJ, Palacio H, et al. Discontinuation of potent antiretroviral therapy: predictive value of and impact on CD4 cell counts and HIV RNA levels. AIDS. 2001;15(16):2101–8.PubMedCrossRef Ahdieh Grant L, Silverberg MJ, Palacio H, et al. Discontinuation of potent antiretroviral therapy: predictive value of and impact on CD4 cell counts and HIV RNA levels. AIDS. 2001;15(16):2101–8.PubMedCrossRef
25.
Zurück zum Zitat O’Brien ME, Clark RA, Besch CL, Myers L, Kissinger P. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr. 2003;34(4):407–14.PubMedCrossRef O’Brien ME, Clark RA, Besch CL, Myers L, Kissinger P. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr. 2003;34(4):407–14.PubMedCrossRef
26.
Zurück zum Zitat Touloumi G, Pantazis N, Antoniou A, et al. Highly active antiretroviral therapy interruption: predictors and virological and immunologic consequences. J Acquir Immune Defic Syndr. 2006;42(5):554–61.PubMedCrossRef Touloumi G, Pantazis N, Antoniou A, et al. Highly active antiretroviral therapy interruption: predictors and virological and immunologic consequences. J Acquir Immune Defic Syndr. 2006;42(5):554–61.PubMedCrossRef
27.
Zurück zum Zitat Holkmann Olsen C, Mocroft A, Kirk O, et al. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death. HIV Med. 2007;8(2):96–104.PubMedCrossRef Holkmann Olsen C, Mocroft A, Kirk O, et al. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death. HIV Med. 2007;8(2):96–104.PubMedCrossRef
28.
Zurück zum Zitat Taffe P, Rickenbach M, Hirschel B, et al. Impact of occasional short interruptions of HAART on the progression of HIV infection: results from a cohort study. AIDS. 2002;16(5):747–55.PubMedCrossRef Taffe P, Rickenbach M, Hirschel B, et al. Impact of occasional short interruptions of HAART on the progression of HIV infection: results from a cohort study. AIDS. 2002;16(5):747–55.PubMedCrossRef
29.
Zurück zum Zitat Li X, Margolick JB, Conover CS, et al. Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr. 2005;38(3):320–8.PubMed Li X, Margolick JB, Conover CS, et al. Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr. 2005;38(3):320–8.PubMed
30.
Zurück zum Zitat Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012;308(4):387–402.PubMedCrossRef Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012;308(4):387–402.PubMedCrossRef
31.
Zurück zum Zitat Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA. 2001;286(20):2568–77.PubMedCrossRef Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA. 2001;286(20):2568–77.PubMedCrossRef
32.
Zurück zum Zitat d’arminio Monforte A, Cozzi-Lepri A, Phillips A, et al. Interruption of highly active antiretroviral therapy in HIV clinical practice: results from the Italian Cohort of Antiretroviral-Naive Patients. J Acquir Immune Defic Syndr. 2005;38(4):407–16.PubMedCrossRef d’arminio Monforte A, Cozzi-Lepri A, Phillips A, et al. Interruption of highly active antiretroviral therapy in HIV clinical practice: results from the Italian Cohort of Antiretroviral-Naive Patients. J Acquir Immune Defic Syndr. 2005;38(4):407–16.PubMedCrossRef
33.
Zurück zum Zitat Radimer KL, Olson CM, Campbell CC. Development of indicators to assess hunger. J Nutr. 1990;120(Suppl 11):1544–8.PubMed Radimer KL, Olson CM, Campbell CC. Development of indicators to assess hunger. J Nutr. 1990;120(Suppl 11):1544–8.PubMed
34.
Zurück zum Zitat Kendall A, Olson CM, Frongillo EA Jr. Validation of the Radimer/Cornell measures of hunger and food insecurity. J Nutr. 1995;125(11):2793–801.PubMed Kendall A, Olson CM, Frongillo EA Jr. Validation of the Radimer/Cornell measures of hunger and food insecurity. J Nutr. 1995;125(11):2793–801.PubMed
35.
Zurück zum Zitat StataCorp LP. Stata statistical software: release 12. TX: College Station; 2011. StataCorp LP. Stata statistical software: release 12. TX: College Station; 2011.
36.
Zurück zum Zitat Moss AR, Hahn JA, Perry S, et al. Adherence to highly active antiretroviral therapy in the homeless population in San Francisco: a prospective study. Clin Infect Dis. 2004;39(8):1190–8.PubMedCrossRef Moss AR, Hahn JA, Perry S, et al. Adherence to highly active antiretroviral therapy in the homeless population in San Francisco: a prospective study. Clin Infect Dis. 2004;39(8):1190–8.PubMedCrossRef
38.
Zurück zum Zitat Tapp C, Milloy MJ, Kerr T, et al. Female gender predicts lower access and adherence to antiretroviral therapy in a setting of free healthcare. BMC Infect Dis. 2011;11:86.PubMedPubMedCentralCrossRef Tapp C, Milloy MJ, Kerr T, et al. Female gender predicts lower access and adherence to antiretroviral therapy in a setting of free healthcare. BMC Infect Dis. 2011;11:86.PubMedPubMedCentralCrossRef
39.
Zurück zum Zitat Spire B, Duran S, Souville M, et al. Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach. Soc Sci Med. 2002;54(10):1481–96.PubMedCrossRef Spire B, Duran S, Souville M, et al. Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach. Soc Sci Med. 2002;54(10):1481–96.PubMedCrossRef
40.
Zurück zum Zitat Lieb S, Brooks RG, Hopkins RS, et al. Predicting death from HIV/AIDS: a case–control study from Florida public HIV/AIDS clinics. J Acquir Immune Defic Syndr. 2002;30(3):351–8.PubMedCrossRef Lieb S, Brooks RG, Hopkins RS, et al. Predicting death from HIV/AIDS: a case–control study from Florida public HIV/AIDS clinics. J Acquir Immune Defic Syndr. 2002;30(3):351–8.PubMedCrossRef
41.
Zurück zum Zitat Johnson MO, Catz SL, Remien RH, et al. Theory-guided, empirically supported avenues for intervention on HIV medication nonadherence: findings from the Healthy Living Project. AIDS Patient Care STDS. 2003;17(12):645–56.PubMedCrossRef Johnson MO, Catz SL, Remien RH, et al. Theory-guided, empirically supported avenues for intervention on HIV medication nonadherence: findings from the Healthy Living Project. AIDS Patient Care STDS. 2003;17(12):645–56.PubMedCrossRef
42.
Zurück zum Zitat Berg KM, Demas PA, Howard AA, Schoenbaum EE, Gourevitch MN, Arnsten JH. Gender differences in factors associated with adherence to antiretroviral therapy. J Gen Intern Med. 2004;19(11):1111–7.PubMedPubMedCentralCrossRef Berg KM, Demas PA, Howard AA, Schoenbaum EE, Gourevitch MN, Arnsten JH. Gender differences in factors associated with adherence to antiretroviral therapy. J Gen Intern Med. 2004;19(11):1111–7.PubMedPubMedCentralCrossRef
43.
Zurück zum Zitat Leaver CA, Bargh G, Dunn JR, Hwang SW. The effects of housing status on health-related outcomes in people living with HIV: a systematic review of the literature. AIDS Behav. 2007;11(6 Suppl):85–100.PubMedCrossRef Leaver CA, Bargh G, Dunn JR, Hwang SW. The effects of housing status on health-related outcomes in people living with HIV: a systematic review of the literature. AIDS Behav. 2007;11(6 Suppl):85–100.PubMedCrossRef
44.
Zurück zum Zitat Mills EJ, Nachega JB, Bangsberg DR, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med. 2006;3(11):e438.PubMedPubMedCentralCrossRef Mills EJ, Nachega JB, Bangsberg DR, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med. 2006;3(11):e438.PubMedPubMedCentralCrossRef
45.
Zurück zum Zitat Udeagu CC, Webster TR, Bocour A, Michel P, Shepard CW. Lost—or just not following up? Public health effort to re-engage HIV-infected persons lost to follow-up into HIV medical care. AIDS. 2013;108(120):2271.CrossRef Udeagu CC, Webster TR, Bocour A, Michel P, Shepard CW. Lost—or just not following up? Public health effort to re-engage HIV-infected persons lost to follow-up into HIV medical care. AIDS. 2013;108(120):2271.CrossRef
Metadaten
Titel
Correlates of Unstructured Antiretroviral Treatment Interruption in a Cohort of HIV-Positive Individuals in British Columbia
verfasst von
Hasina Samji
Yalin Chen
Kate Salters
Julio S. G. Montaner
Robert S. Hogg
Publikationsdatum
01.11.2014
Verlag
Springer US
Erschienen in
AIDS and Behavior / Ausgabe 11/2014
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-014-0776-1

Weitere Artikel der Ausgabe 11/2014

AIDS and Behavior 11/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

VHF-Ablation nützt wohl nur bei reduzierter Auswurfleistung

02.05.2024 Ablationstherapie Nachrichten

Ob die Katheterablation von Vorhofflimmern bei Patienten mit Herzinsuffizienz die Komplikationsraten senkt, scheint davon abzuhängen, ob die Auswurfleistung erhalten ist oder nicht. Das legen die Ergebnisse einer Metaanalyse nahe.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.